Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia (ACAD) Q2 Revenue Rises 9%
11:48pm, Wednesday, 06'th Aug 2025
Acadia (ACAD) Q2 Revenue Rises 9%
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
06:16pm, Wednesday, 06'th Aug 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
04:05pm, Wednesday, 06'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025. “Acadia continued to build momentum in the se
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
04:05pm, Monday, 04'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Scott Cenci as Senior Vice President, Chief Information and Data Officer. In this role, Scott
GMAB vs. ACAD: Which Stock Is the Better Value Option?
12:41pm, Friday, 01'st Aug 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Acadia Pharmaceuticals (ACAD). But which of these two stocks off
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
11:07am, Wednesday, 30'th Jul 2025
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In
04:32am, Monday, 28'th Jul 2025
ACADIA's valuation is justified by strong revenue growth from NUPLAZID and DAYBUE, with total 2025 revenue guidance of $1B–$1.1B. ACP-101's phase 3 trial for Prader-Willi syndrome is a high-risk cat
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
08:00am, Thursday, 10'th Jul 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
KMDA or ACAD: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 04'th Jul 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Acadia Pharmaceuticals (ACAD). But which of these two stocks offers value investors a better
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 03'rd Jul 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted ind
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
08:00am, Wednesday, 25'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will host its inaugural 2025 R&D Day today to highlight its key pipeline programs and their potential to drive long-term growth.
KMDA vs. ACAD: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 18'th Jun 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada (KMDA) or Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attract
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 17'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on June 6, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted ind
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for
Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?
12:36pm, Friday, 06'th Jun 2025
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
